Patent intelligence · US
US 9057069
Compositions and methods for inhibiting expression of Eg5 gene
Compositions and methods for inhibiting expression of Eg5 gene
Patent details — US 9057069
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 16, 2015
- Expiration
- Jun 11, 2035
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Claims
- 27
- CPC classes
- A61P, A61P35/00, A61P43/00
Quick answer
US 9057069 (Compositions and methods for inhibiting expression of Eg5 gene) is held by Alnylam Pharmaceuticals, Inc.. Status: granted. Granted Jun 16, 2015. Expires Jun 11, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61P, A61P35/00, A61P43/00
More from Alnylam Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12416006
Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof
granted -
US 12404508
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
granted -
US 12397013
Extrahepatic delivery
granted -
US 12385043
Modified double-stranded RNA agents
granted -
US 12385044
Modified double-stranded RNA agents
granted -
US 12378553
Modified double-stranded RNA agents
granted -
US 12364762
Biodegradable lipids for the delivery of active agents
granted -
US 12350338
Biodegradable lipids for the delivery of active agents
granted
Frequently asked questions
What is US patent 9057069?
US 9057069 (Compositions and methods for inhibiting expression of Eg5 gene) is held by Alnylam Pharmaceuticals, Inc.. Status: granted. Granted Jun 16, 2015. Expires Jun 11, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9057069?
Alnylam Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 379 pharmaceutical patents for this assignee.
When does US 9057069 expire?
Our index shows an expiration date of Jun 11, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.